Auxilium’s Peyronie’s Strategy: Start With Few Urologists, Broad Patient Population

Xiaflex is first drug approved for Peyronie’s disease; initial marketing will focus on physicians that already provide invasive treatment.

Auxilium Pharmaceuticals Inc. will focus its initial marketing efforts of Xiaflex (collagenase clostridium histolyticum) for Peyronie’s disease patients to the small population of urologists who currently treat the disease invasively, before branching out to target the majority of urologists.

The Dec. 6 approval of Auxilium’s sBLA makes Xiaflex the first medicine and non-surgical option to treat men with the...